Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).
暂无分享，去创建一个
S. Culine | G. Gravis | F. Joly | P. Barthélémy | C. Théodore | K. Fizazi | P. Beuzeboc | E. Bompas | I. Borget | J. Berdah | Y. Tazi | G. Baciarello | M. Deblock | G. Martineau | R. Delva | T. N. T. Hon | C. Cheneau | A. Flechon | M. Gross‐Goupil | T. Lharidon